A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients
Latest Information Update: 17 Jun 2025
At a glance
- Drugs EPIC 321 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors EPIC BIO
Most Recent Events
- 11 May 2025 Status changed from not yet recruiting to recruiting.
- 06 May 2025 Planned initiation date changed from 1 May 2025 to 20 May 2025.
- 06 May 2025 Status changed from recruiting to not yet recruiting.